Focused On-demand Library for Elongation factor Ts, mitochondrial

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P43897

UPID:

EFTS_HUMAN

Alternative names:

Alternative UPACC:

P43897; B4E391; F5H2T7; Q561V7; Q8TBC2; Q9UQK0

Background:

Elongation factor Ts, mitochondrial (EF-Ts, mitochondrial), encoded by the gene with accession number P43897, plays a pivotal role in protein synthesis. It facilitates the exchange of GDP to GTP, remaining bound to the aminoacyl-tRNA.EF-Tu.GTP complex during the GTP hydrolysis stage on the ribosome. This process is crucial for the efficient translation of genetic information into functional proteins.

Therapeutic significance:

The protein is implicated in Combined oxidative phosphorylation deficiency 3, a mitochondrial disease characterized by severe metabolic acidosis and encephalomyopathy or hypertrophic cardiomyopathy. This association highlights the protein's potential as a target for therapeutic intervention in mitochondrial disorders.